Un trastorno que disminuye la calidad de vida | 23 AGO 19

Gastroparesia

Los mecanismos de inervación y vaciamiento gástrico y sus alteraciones, además del diagnóstico y el tratamiento de la gastroparesia
Autor/a: Camilleri M, Chedid V, Ford AC, et al. Nature Reviews 2018
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

1. Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L. & Gerson, L. American College of Gastroenterology clinical guideline: management of gastroparesis. Am. J. Gastroenterol. 108, 18–37 (2013). This paper presents the most recent clinical guideline for the management of gastroparesis.

2. Mearin, F. et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastro- enteritis outbreak: one- year follow- up cohort study. Gastroenterology 129, 98–104 (2005).

3. Thumshirn, M. et al. Gastric accommodation in non-ulcer dyspepsia and the roles of Helicobacter pylori infection and vagal function. Gut 44, 55–64 (1999).

4. Tack, J. et al. Clinical and pathophysiological characteristics of acute- onset functional dyspepsia. Gastroenterology 122, 1738–1747 (2002).

5. Vassallo, M., Camilleri, M., Caron, B. L. & Low, P. A. Gastrointestinal motor dysfunction in acquired selective cholinergic dysautonomia associated with infectious mononucleosis. Gastroenterology 100, 252–258 (1991).

6. Pasricha, P. J. & Parkman, H. P. Gastroparesis: definitions and diagnosis. Gastroenterol. Clin. N. Am. 44, 1–7 (2015).

7. Enck, P. et al. Functional dyspepsia. Nat. Rev. Dis. Primers 3, 17081 (2017). This Review presents an excellent synthesis of the state of the art and science in functional dyspepsia.

8. Park, S. Y. et al. Gastric motor dysfunction in patients with functional gastroduodenal symptoms. Am. J. Gastroenterol. 112, 1689–1699 (2017). This paper presents data on different pathophysiological subgroups in almost 1,300 patients with upper GI symptoms.

9. Stanghellini, V. et al. Gastroduodenal disorders. Gastroenterology 150, 1380–1392 (2016). This paper presents the most recent Rome IV document on upper GI dysfunctions and related symptom complexes.

10. Stanghellini, V. & Tack, J. Gastroparesis: separate entity or just a part of dyspepsia? Gut 63, 1972–1978 (2014).

11. Parkman, H. P. et al. Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology 140, 101–115 (2011).

12. Soykan, I., Sivri, B., Sarosiek, I., Kiernan, B. & McCallum, R. W. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long- term follow- up of patients with gastroparesis. Dig. Dis. Sci. 43, 2398–2404 (1998).

13. Aleppo, G. et al. Reported gastroparesis in adults with type 1 diabetes (T1D) from the T1D Exchange clinic registry. J. Diabetes Compl. 31, 1669–1673 (2017).

14. Bytzer, P. et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus. Arch. Intern. Med. 161, 1989–1996 (2001).

15. Maleki, D. et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch. Intern. Med. 160, 2808–2816 (2000).

16. Jung, H. K. et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology 136, 1225–1233 (2009). This paper presents a strong epidemiological study on gastroparesis. 17. Rey, E. et al. Prevalence of hidden gastroparesis in the community: the gastroparesis “iceberg”. J. Neurogastroenterol. Motil. 18, 34–42 (2012).

18. Ravella, K. et al. Chronic estrogen deficiency causes gastroparesis by altering neuronal nitric oxide synthase function. Dig. Dis. Sci. 58, 1507–1515 (2013).

19. Showkat Ali, M. et al. Gender and estradiol as major factors in the expression and dimerization of nNOSalpha in rats with experimental diabetic gastroparesis. Dig. Dis. Sci. 57, 2814–2825 (2012).

20. Boaz, M., Kislov, J., Dickman, R. & Wainstein, J. Obesity and symptoms suggestive of gastroparesis in patients with type 2 diabetes and neuropathy. J. Diabetes Compl. 25, 325–328 (2011). 21. Pasricha, P. J. et al. Outcomes and factors associated with reduced symptoms in patients with gastroparesis. Gastroenterology 149, 1762–1774 (2015).

22. Choung, R. S. et al. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am. J. Gastroenterol. 107, 82–88 (2012).

23. Dickman, R. et al. Prevalence of symptoms suggestive of gastroparesis in a cohort of patients with diabetes mellitus. J. Diabetes Compl. 27, 376–379 (2013).

24. Kofod- Andersen, K. & Tarnow, L. Prevalence of gastroparesis- related symptoms in an unselected cohort of patients with type 1 diabetes. J. Diabetes Compl. 26, 89–93 (2012).

25. Almogbel, R. A., Alhussan, F. A., Alnasser, S. A. & Algeffari, M. A. Prevalence and risk factors of gastroparesis- related symptoms among patients with type 2 diabetes. Intl. J. Health Sci. 10, 397–404 (2016).

26. Bharucha, A. E. et al. Delayed gastric emptying is associated with early and long- term hyperglycemia in type 1 diabetes mellitus. Gastroenterology 149, 330–339 (2015). This article presents an important longitudinal study of diabetes complications including gastroparesis.

27. Phillips, L. K., Deane, A. M., Jones, K. L., Rayner, C. K. & Horowitz, M. Gastric emptying and glycaemia in health and diabetes mellitus. Nat. Rev. Endocrinol. 11, 112–128 (2015).

28. Boronikolos, G. C. et al. Upper gastrointestinal motility and symptoms in individuals with diabetes, prediabetes and normal glucose tolerance. Diabetologia 58, 1175–1182 (2015).

29. Jones, K. L. et al. A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus. Am. J. Med. 113, 449–455 (2002).

30. Kong, M. F., Horowitz, M., Jones, K. L., Wishart, J. M. & Harding, P. E. Natural history of diabetic gastroparesis. Diabetes Care 22, 503–507 (1999).

31. Chang, J., Rayner, C. K., Jones, K. L. & Horowitz, M. Prognosis of diabetic gastroparesis—a 25-year evaluation. Diabetes Med. 30, e185–e188 (2013). This important article describes the natural history of diabetic gastroparesis.

32. Wang, Y. R., Fisher, R. S. & Parkman, H. P. Gastroparesis- related hospitalizations in the United States: Trends, characteristics, and outcomes, 1995–2004. Am. J. Gastroenterol. 103, 313–322 (2008).

33. Hirsch, W. et al. Emergency department burden of gastroparesis in the United States, 2006 to 2013.

J. Clin. Gastroenterol. https://doi.org/10.1097/ MCG.0000000000000972 (2017). 34. Wadhwa, V. et al. Healthcare utilization and costs associated with gastroparesis. World J. Gastroenterol. 23, 4428–4436 (2017).

35. Nusrat, S. & Bielefeldt, K. Gastroparesis on the rise: Incidence versus awareness? Neurogastroenterol. Motil. 25, 16–22 (2013).

36. Uppalapati, S. S., Ramzan, Z., Fisher, R. S. & Parkman, H. P. Factors contributing to hospitalization for gastroparesis exacerbations. Dig. Dis. Sci. 54, 2404–2409 (2009).

37. Bielefeldt, K. Regional differences in healthcare delivery for gastroparesis. Dig. Dis. Sci. 58, 2789–2798 (2013).

38. Bielefeldt, K. Factors influencing admission and outcomes in gastroparesis. Neurogastroenterol. Motil. 25, 389–398 (2013).

39. Hyett, B. et al. Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology 137, 445–452 (2009). This paper provides the details of the morbidity and complications of diabetic gastroparesis.

40. Meyer, J. H., Thomson, J. B., Cohen, M. B., Shadchehr, A. & Mandiola, S. A. Sieving of solid food by the canine stomach and sieving after gastric surgery. Gastroenterology 76, 804–813 (1979).

41. Meyer, J. H., Elashoff, J., Porter- Fink, V., Dressman, J. & Amidon, G. L. Human postprandial gastric emptying of 1-3-millimeter spheres. Gastroenterology 94, 1315–1325 (1988).

42. Grider, J. R. & Makhlouf, G. M. Regulation of the peristaltic reflex by peptides of the myenteric plexus. Arch. Int. Pharmacodyn. Ther. 303, 232–251 (1990).

43. Sanders, K. M., Ward, S. M. & Koh, S. D. Interstitial cells: regulators of smooth muscle function. Physiol. Rev. 94, 859–907 (2014). This important review discusses the pacemaker cells in the GI tract.

44. Grover, M. et al. Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology 140, 1575–1585 (2011).

45. Bernard, C. E. et al. Association of low numbers of CD206-positive cells with loss of ICC in the gastric body of patients with diabetic gastroparesis. Neurogastroenterol. Motil. 26, 1275–1284 (2014).

46. Herring, B. P. et al. Idiopathic gastroparesis is associated with specific transcriptional changes in the gastric muscularis externa. Neurogastroenterol. Motil. 30, e13230 (2018).

47. Stadler, K. Oxidative stress in diabetes. Adv. Exp. Med. Biol. 771, 272–287 (2012).

48. Han, B., Li, X. & Hao, J. The cholinergic anti-inflammatory pathway: an innovative treatment strategy for neurological diseases. Neurosci. Biobehav. Rev. 77, 358–368 (2017).

49. Grover, M. et al. Clinical- histological associations in gastroparesis: results from the Gastroparesis Clinical Research Consortium. Neurogastroenterol. Motil. 24, 531–539 (2012).

50. Hayashi, Y. et al. Hyperglycemia increases interstitial cells of Cajal via MAPK1 and MAPK3 signaling to ETV1 and KIT, leading to rapid gastric emptying. Gastroenterology 153, 521–535 (2017). 51. Choi, K. M. et al. Heme oxygenase-1 protects interstitial cells of Cajal from oxidative stress and reverses diabetic gastroparesis. Gastroenterology 135, 2055–2064 (2008).

52. Yamada, N. et al. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am. J. Hum. Genet. 66, 187–195 (2000).

53. Chen, Y. H. et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum. Genet. 111, 1–8 (2002).

54. Gibbons, S. J. et al. Repeat polymorphisms in the Homo sapiens heme oxygenase-1 gene in diabetic and idiopathic gastroparesis. PLOS ONE 12, e0187772 (2017).

55. Grover, M. et al. Platelet- derived growth factor receptor alpha (PDGFRalpha)-expressing “fibroblastlike cells” in diabetic and idiopathic gastroparesis of humans. Neurogastroenterol. Motil. 24, 844–852 (2012).

56. Bytzer, P. et al. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am. J. Gastroenterol. 97, 604–611 (2002).

57. Gaber, A. O. et al. Changes in gastric emptying in recipients of successful combined pancreas- kidney transplants. Dig. Dis. 9, 437–443 (1991).

58. Coleski, R. & Hasler, W. L. Coupling and propagation of normal and dysrhythmic gastric slow waves during acute hyperglycaemia in healthy humans. Neurogastroenterol. Motil. 21, 492–499 (2009).

59. Fraser, R. J. et al. Hyperglycaemia slows gastric emptying in type 1 (insulin- dependent) diabetes mellitus. Diabetologia 33, 675–680 (1990).

60. Schvarcz, E. et al. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin- dependent diabetes mellitus. Gastroenterology 113, 60–66 (1997).

61. Russo, A. et al. Insulin- induced hypoglycaemia accelerates gastric emptying of solids and liquids in long- standing type 1 diabetes. J. Clin. Endocrinol. Metab. 90, 4489–4495 (2005).

62. Bharucha, A. E., Camilleri, M., Forstrom, L. A. & Zinsmeister, A. R. Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin. Endocrinol. (Oxf.) 70, 415–420 (2009).

63. Holzapfel, A. et al. Gastric emptying in Type II (non-insulin-dependent) diabetes mellitus before and after therapy readjustment: no influence of actual blood glucose concentration. Diabetologia 42, 1410–1412 (1999).

64. Chang, J. et al. A 25-year longitudinal evaluation of gastric emptying in diabetes. Diabetes Care 35, 2594–2596 (2012).

65. Halland, M. & Bharucha, A. E. Relationship between control of glycemia and gastric emptying disturbances in diabetes mellitus. Clin. Gastroenterol. Hepatol. 14, 929–936 (2016).

66. Laway, B. A., Malik, T. S., Khan, S. H. & Rather, T. A. Prevalence of abnormal gastric emptying in asymptomatic women with newly detected diabetes and its reversibility after glycemic control – a prospective case control study. J. Diabetes Compl. 27, 78–81 (2013).

67. Vella, A. et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 56, 1475–1480 (2007).

68. Berry, R. et al. Patterns of abnormal gastric pacemaking after sleeve gastrectomy defined by laparoscopic high- resolution electrical mapping. Obes. Surg. 27, 1929–1937 (2017).

69. Vigneshwaran, B. et al. Impact of sleeve gastrectomy on type 2 diabetes mellitus, gastric emptying time, glucagon- like peptide 1 (GLP-1), ghrelin and leptin in non- morbidly obese subjects with BMI 30–35.0 kg/m2: a prospective study. Obes. Surg. 26, 2817–2823 (2016).

70. Camilleri, M., Lembo, A. & Katzka, D. A. Opioids in gastroenterology: treating adverse effects and creating therapeutic benefits. Clin. Gastroenterol. Hepatol. 15, 1338–1349 (2017).

71. Galligan, J. J. & Akbarali, H. I. Molecular physiology of enteric opioid receptors. Am. J. Gastroenterol. Suppl. 2, 17–21 (2014).

72. Camilleri, M. et al. Dose- related effects of synthetic human beta- endorphin and naloxone on fed gastrointestinal motility. Am. J. Physiol. 251, G147–G154 (1986).

73. Reynolds, J. C., Ouyang, A. & Cohen, S. Evidence for an opiate- mediated pyloric sphincter reflex. Am. J. Physiol. 246, G130–G136 (1984).

74. Parkman, H. P. et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin. Gastroenterol. Hepatol. 9, 1056–1064 (2011).

75. Parkman, H. P. et al. Nausea and vomiting in gastroparesis: similarities and differences in idiopathic and diabetic gastroparesis. Neurogastroenterol. Motil. 28, 1902–1914 (2016). This paper provides an important summary of the features of idiopathic and diabetic gastroparesis observed in the NIH Gastroparesis Consortium study in United States.

76. Parkman, H. P. et al. Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing. Neurogastroenterol. Motil. 29, e12981 (2017).

77. Hasler, W. L. et al. Bloating in gastroparesis: severity, impact, and associated factors. Am. J. Gastroenterol. 106, 1492–1502 (2011).

78. Jehangir, A. & Parkman, H. P. Chronic opioids in gastroparesis: relationship with gastrointestinal symptoms, healthcare utilization and employment. World J. Gastroenterol. 23, 7310–7320 (2017).

79. Maranki, J. L. et al. Predictive factors for clinical improvement with Enterra gastric electric stimulation treatment for refractory gastroparesis. Dig. Dis. Sci. 53, 2072–2078 (2008).

80. Oh, J. J. & Kim, C. H. Gastroparesis after a presumed viral illness: clinical and laboratory features and natural history. Mayo. Clin. Proc. 65, 636–642 (1990).

81. Naftali, T., Yishai, R., Zangen, T. & Levine, A. Post- infectious gastroparesis: clinical and electrogastrographic aspects. J. Gastroenterol. Hepatol. 22, 1423–1428 (2007).

82. Tack, J., Bisschops, R. & Sarnelli, G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 127, 1239–1255 (2004).

This classic paper describes different pathophysiological subgroups in a large number of patients with functional dyspepsia, including delayed emptying and reduced gastric accommodation.

83. Talley, N. J. et al. Impact of chronic gastrointestinal symptoms in diabetes mellitus on health- related quality of life. Am. J. Gastroenterol. 96, 71–76 (2001).

84. Revicki, D. A. et al. Development and validation of a patient- assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment. Pharmacol. Ther. 18, 141–150 (2003).

85. Revicki, D. A. et al. Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index- Daily Diary (GCSI- DD). Neurogastroenterol. Motil. 24, 456–463 (2012).

86. Ricci, J. A. et al. Upper gastrointestinal symptoms in a U. S. national sample of adults with diabetes. Scand. J. Gastroenterol. 35, 152–159 (2000).

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024